Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

NCT04566445 is registered in ClinicalTrials.gov with Gyroscope Therapeutics Limited as lead sponsor.

NCT NCT04566445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04566445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Lead sponsor
Gyroscope Therapeutics Limited
Phase
Phase 2
Overall status
Terminated
Start date
September 28, 2020
Completion date
June 10, 2024
Enrollment
255 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration